{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:39:32Z","timestamp":1763141972697,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clinthera.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:16:48Z","timestamp":1672186608000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-1278","authenticated-orcid":false,"given":"J.D.","family":"Hammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Furtney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-0539","authenticated-orcid":false,"given":"Swati","family":"Agarwal-Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.12.003_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":"The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0002","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1542\/peds.81.5.697","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results","volume":"81","year":"1988","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0003","first-page":"233","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0004","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0006","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0007","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0008","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0009","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0011","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcjo.2017.09.028","article-title":"Late onset tractional fibrovascular proliferation post intravitreal bevacizumab following treatment of retinopathy of prematurity","volume":"53","author":"Agarwal-Sinha","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","article-title":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina","volume":"55","author":"Gonzalez","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0016","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0017","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0018","article-title":"Computer-aided diagnosis of retinopathy in retinal fundus images of preterm infants via quantification of vascular tortuosity","volume":"3","author":"Oloumi","year":"2016","journal-title":"J Med Imaging (Bellingham)"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2022.12.003_bib0019","first-page":"53","article-title":"Fluorescein angiography and retinal vascular development in premature infants","volume":"25","author":"Purcaro","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0020","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.ophtha.2015.02.018","article-title":"Author reply","volume":"122","author":"Lepore","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18314\/ctoy.v1i1.1247","article-title":"Preferences and trends in practices caring premature infants for retinopathy of prematurity (ROP): a web-based survey","volume":"1","author":"Agarwal-Sinha","year":"2018","journal-title":"Curr Trends Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0023","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics."},{"key":"10.1016\/j.clinthera.2022.12.003_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J Am Acad Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0026","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0027","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1167\/iovs.12-9516","article-title":"Eye size in threshold retinopathy of prematurity, based on a Danish preterm infant series: early axial eye growth, pre- and postnatal aspects","volume":"53","author":"Fledelius","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0028","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archopht.1985.01050060045020","article-title":"Refractive development of the human eye","volume":"103","author":"Gordon","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0029","first-page":"815","article-title":"Axial length development in children","volume":"12","author":"Bach","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0030","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1167\/iovs.04-1040","article-title":"Axial growth and changes in lenticular and corneal power during emmetropization in infants","volume":"46","author":"Mutti","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0031","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1167\/iovs.12-10713","article-title":"Distribution and determinants of eye size and shape in newborn children: a magnetic resonance imaging analysis","volume":"54","author":"Lim","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0032","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1167\/iovs.11-7221","article-title":"Quantitative evaluation of changes in eyeball shape in emmetropization and myopic changes based on elliptic Fourier descriptors","volume":"52","author":"Ishii","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0033","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1167\/iovs.04-1506","article-title":"Shape of the retinal surface in emmetropia and myopia","volume":"46","author":"Atchison","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0034","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0035","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1167\/iovs.13-13397","article-title":"Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy","volume":"55","author":"Tokunaga","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-vegf therapy as a treatment for retinopathy of prematurity: what we know after 7 years","volume":"52","author":"Klufas","year":"2015","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0038","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000509380","article-title":"Efficacy of aflibercept treatment and its effect on the retinal perfusion in the oxygen-induced retinopathy mouse model of retinopathy of prematurity","volume":"64","author":"Amin","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0039","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Pediatric Eye Disease Investigator Group. Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0041","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"Henaine-Berra","year":"2014","journal-title":"J Am Acad Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0042","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","article-title":"Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0043","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3928\/01913913-20190923-03","article-title":"Neurodevelopmental effect of general anesthesia on the pediatric patient","volume":"56","author":"Cavuoto","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0044","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/pan.13455","article-title":"Anesthesia and the developing brain: a way forward for laboratory and clinical research","volume":"28","author":"Disma","year":"2018","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000475928","article-title":"Effect of anesthesia on the developing brain: infant and fetus","volume":"43","author":"Andropoulos","year":"2018","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0046","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/ACO.0000000000000520","article-title":"Clinical update regarding general anesthesia-associated neurotoxicity in infants and children","volume":"30","author":"Graham","year":"2017","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/ACO.0000000000000461","article-title":"Update on developmental anesthesia neurotoxicity","volume":"30","author":"Vutskits","year":"2017","journal-title":"Curr Opin Anaesthesiol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2022.12.003_bib0048","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1093\/bja\/aeq302","article-title":"Early childhood general anaesthesia exposure and neurocognitive development","volume":"105","author":"Sun","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0049","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA Review Results in New Warnings About Using General Anesthetics and Sedation Drugs in Young Children and Pregnant Women [FDA website]. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-review-results-new-warnings-about-using-general-anesthetics-and. Accessed July 5, 2021."},{"key":"10.1016\/j.clinthera.2022.12.003_bib0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMp1700196","article-title":"Anesthesia and developing brains\u2014implications of the FDA warning","volume":"376","author":"Andropoulos","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0051","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(15)00608-X","article-title":"Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial","volume":"387","author":"Davidson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0052","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/jama.2016.6967","article-title":"Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood","volume":"315","author":"Sun","year":"2016","journal-title":"JAMA"},{"issue":"10172","key":"10.1016\/j.clinthera.2022.12.003_bib0053","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(18)32485-1","article-title":"GAS Consortium. Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised controlled equivalence trial","volume":"393","author":"McCann","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0054","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.bja.2019.01.022","article-title":"Patterns of neuropsychological changes after general anaesthesia in young children: secondary analysis of the Mayo Anesthesia Safety in Kids study","volume":"122","author":"Zaccariello","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2022.12.003_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ANA.0000000000000538","article-title":"Report on the Sixth Pediatric Anesthesia Neurodevelopmental Assessment (PANDA) symposium: anesthesia and neurodevelopment in children","volume":"31","author":"Lee","year":"2019","journal-title":"J Neurosurg Anesthesiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822004076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822004076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:21Z","timestamp":1758963501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822004076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0149291822004076"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.12.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}